FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3093491510> ?p ?o ?g. }

• W3093491510 endingPage "199" @default.
• W3093491510 startingPage "198" @default.
• W3093491510 abstract "In a post-hoc analysis of TOPCAT,1 25% of patients with heart failure and preserved ejection fraction who took spironolactone discontinued the drug during the first year, mainly due to hyperkalaemia and worsening renal function. The discontinuation was associated with a higher risk of subsequent events including hospitalization for heart failure, cardiovascular death and all-cause mortality.1 However, a concomitant use of alternative diuretics, in particular loop diuretics, should have been investigated in greater detail. In patients with heart failure, a combined use of diuretics including mineralocorticoid receptor antagonists, loop diuretics and thiazides is a common therapeutic approach involving increased doses of diuretics with the progression of cardiorenal syndrome and development of diuretic resistance.2, 3 Both spironolactone use and its dose have been closely correlated with markers of heart failure severity such as left ventricular ejection fraction, cardiac troponin I levels and N-terminal pro brain natriuretic peptide levels.3 Patients with heart failure who receive higher doses of spironolactone often concomitantly use a loop diuretic.3 In a companion paper in the Journal,4 an additional analysis of the same TOPCAT Americas population confirmed that 76% of patients taking spironolactone also used loop diuretics. The adverse effects of loop diuretics include dehydration, hypovolaemia, hypokalaemia, hypomagnesaemia, hyponatraemia, and hypocalcaemia, which may lead to discontinuation or reduction in the diuretic dose.2 Because of the tendency toward hypokalaemia, loop diuretics probably have affected potassium levels in 76% of the TOPCAT participants who concomitantly took both drugs. This could have produced an underestimation of the spironolactone effect on hyperkalaemia. In addition, the use of furosemide may cause hyponatraemia,2, 3 especially when combined with spironolactone,3 which may be an added reason for diuretic discontinuation or dose reduction.2 We also reported that on average hyponatraemic patients have higher serum potassium.3 The second important issue is that loop diuretics may independently adversely affect renal function through activation of the renin–angiotensin–aldosterone system and renal vasoconstriction.4-6 In a study involving stable patients with heart failure, the reduction of furosemide dose by 50% for 3 weeks was associated with a significant improvement in renal function and a trend toward plasma renin decrease among those with glomerular filtration rate <60 mL/min/1.73 m2.5 In another study also involving patients with stable heart failure, a reduction of furosemide dose of ≥120 mg to a third of the baseline dose was associated with increased 2-year survival rates free of hospitalization or cardiac death and significantly less frequent deterioration of renal function.6 Given the frequency of the parallel use of spironolactone and loop diuretic in the TOPCAT population,4 without accounting for the data on loop diuretics, we cannot be completely sure that the decline in renal function is solely the result of higher spironolactone dosage, i.e. the effect could be overestimated. Spironolactone and loop diuretics are often concomitantly used, which could have affected the TOPCAT results. A crosstalk among haemodynamic and neurohumoral effects of diuretic use on renal function and serum electrolyte levels should be further investigated in order to avoid spironolactone discontinuation in patients with heart failure." @default.
• W3093491510 created "2020-10-29" @default.
• W3093491510 creator A5059565574 @default.
• W3093491510 creator A5087182493 @default.
• W3093491510 date "2020-11-03" @default.
• W3093491510 modified "2023-10-18" @default.
• W3093491510 title "Spironolactone discontinuation in patients with heart failure: complex interactions with loop diuretics. Letter regarding the article ‘Spironolactone dose in heart failure with preserved ejection fraction: findings from TOPCAT’" @default.
• W3093491510 cites W1999533316 @default.
• W3093491510 cites W2098585282 @default.
• W3093491510 cites W2166217979 @default.
• W3093491510 cites W3030967944 @default.
• W3093491510 cites W3032634451 @default.
• W3093491510 cites W3046318559 @default.
• W3093491510 doi "https://doi.org/10.1002/ejhf.2031" @default.
• W3093491510 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33094888" @default.
• W3093491510 hasPublicationYear "2020" @default.
• W3093491510 type Work @default.
• W3093491510 sameAs 3093491510 @default.
• W3093491510 citedByCount "1" @default.
• W3093491510 countsByYear W30934915102022 @default.
• W3093491510 crossrefType "journal-article" @default.
• W3093491510 hasAuthorship W3093491510A5059565574 @default.
• W3093491510 hasAuthorship W3093491510A5087182493 @default.
• W3093491510 hasBestOaLocation W30934915101 @default.
• W3093491510 hasConcept C126322002 @default.
• W3093491510 hasConcept C164705383 @default.
• W3093491510 hasConcept C2776379505 @default.
• W3093491510 hasConcept C2777955127 @default.
• W3093491510 hasConcept C2778198053 @default.
• W3093491510 hasConcept C2778715236 @default.
• W3093491510 hasConcept C2779918671 @default.
• W3093491510 hasConcept C2781117629 @default.
• W3093491510 hasConcept C2908647359 @default.
• W3093491510 hasConcept C71924100 @default.
• W3093491510 hasConcept C78085059 @default.
• W3093491510 hasConcept C99454951 @default.
• W3093491510 hasConceptScore W3093491510C126322002 @default.
• W3093491510 hasConceptScore W3093491510C164705383 @default.
• W3093491510 hasConceptScore W3093491510C2776379505 @default.
• W3093491510 hasConceptScore W3093491510C2777955127 @default.
• W3093491510 hasConceptScore W3093491510C2778198053 @default.
• W3093491510 hasConceptScore W3093491510C2778715236 @default.
• W3093491510 hasConceptScore W3093491510C2779918671 @default.
• W3093491510 hasConceptScore W3093491510C2781117629 @default.
• W3093491510 hasConceptScore W3093491510C2908647359 @default.
• W3093491510 hasConceptScore W3093491510C71924100 @default.
• W3093491510 hasConceptScore W3093491510C78085059 @default.
• W3093491510 hasConceptScore W3093491510C99454951 @default.
• W3093491510 hasIssue "1" @default.
• W3093491510 hasLocation W30934915101 @default.
• W3093491510 hasOpenAccess W3093491510 @default.
• W3093491510 hasPrimaryLocation W30934915101 @default.
• W3093491510 hasRelatedWork W2040618276 @default.
• W3093491510 hasRelatedWork W2042079149 @default.
• W3093491510 hasRelatedWork W2046071402 @default.
• W3093491510 hasRelatedWork W2053109504 @default.
• W3093491510 hasRelatedWork W2061825906 @default.
• W3093491510 hasRelatedWork W2147938679 @default.
• W3093491510 hasRelatedWork W2469138218 @default.
• W3093491510 hasRelatedWork W3046112283 @default.
• W3093491510 hasRelatedWork W3093491510 @default.
• W3093491510 hasRelatedWork W4280580214 @default.
• W3093491510 hasVolume "23" @default.
• W3093491510 isParatext "false" @default.
• W3093491510 isRetracted "false" @default.
• W3093491510 magId "3093491510" @default.
• W3093491510 workType "article" @default.